Figure1 (Duloxetine Fig1)
Duloxetine Capsule, Delayed Release
Product Images NDC 71335-2017
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-2017). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure10 (Duloxetine Fig10)
Figure2 (Duloxetine Fig2)
The graph shows the proportion of patients with relapse over time after randomization to receive either a placebo or duloxetine for treatment. The x-axis represents time in days and the y-axis represents the percentage of patients with relapse. Duloxetine appears to have a lower proportion of patients with relapse compared to the placebo group.*
Figure3 (Duloxetine Fig3)
The text appears to be a table showing the percentage of patients improved with different treatments, including Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and Placebo. The table also includes the percent improvement in pain from baseline for each treatment.*
Figure4 (Duloxetine Fig4)
Figure5 (Duloxetine Fig5)
The text is describing a chart or graph that displays the percentage of patients who have improved with different treatments. The chart includes three different treatments; Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and a placebo. The percentage of patients improved is at 100% for Duloxetine 60mg twice daily, and the other two treatments are represented as a comparison with this. The chart also displays the percent improvement in pain from the baseline.*
Figure6 (Duloxetine Fig6)
Figure8 (Duloxetine Fig8)
The text describes a medication called Placebo with Duloxetine 60/120 mg dosage to be taken once daily. The other texts appear to be gibberish and not useful for generating a description. The last line indicates data related to improvement in pain from baseline.*
Figure9 (Duloxetine Fig9)
The text describes a comparison between placebo and duloxetine 60 mg taken once a day. The next part of the text appears to include a chart that shows percent improvement in pain from baseline after taking either placebo or duloxetine.*
Structure (Duloxetine Structure)
Label (Lbl713352017)
This is packaging information for a medication, specifically indicating that it is a capsule of 30mg strength. The name of the medication is not specified, but it is being compared to Cymbalta 30mg Capsule. The manufacturer is Ajanta Pharma Limited and the package contains 30 capsules. The expiration date is not explicitly stated, but is indicated as MM/YY (month/year). The medication may cause drowsiness and should be stored at room temperature. There is also a NDC (National Drug Code) number provided.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
